Sino Biopharmaceutical Ltd's Fiscal Year is From January To December - All Figures are in HKD, Billions.
The item "Ebitda" stands at 6.05 Billion Hong Kong Dollars for the trailing twelve months (TTM) period ending 06/30/2025, the highest value since 09/30/2023.
Sino Biopharmaceutical Ltd's second quarter result of 1.97 Billion HKD for the item "Ebitda" represents no change compared to it's first quarter result.
Also, Sino Biopharmaceutical Ltd's second quarter result of 1.97 Billion HKD for the item "Ebitda" represents an increase of 7.08 percent compared to it's second quarter result of last year.
Looking again at the trailing twelve months series (TTM), Sino Biopharmaceutical Ltd's second quarter result of 6.05 Billion HKD for the item "Ebitda" represents an increase of 2.20 percent compared to it's first quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 58.56 percent compared to the value the year prior.
The 1 year change in percent is 58.56.
The 3 year change in percent is 8.58.
The 5 year change in percent is -0.5875.
The 10 year change in percent is 135.26.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Ebitda | 905,699,262,464.00 |
![]() | Johnson & Johnson - Ebitda | 486,508,953,600.00 |
![]() | AbbVie Inc - Ebitda | 399,570,305,024.00 |
![]() | Roche Holding AG - Ebitda | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Ebitda | 280,205,508,085.11 |